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Abstract
Background: Obtaining the necessary approvals and permission for clinical research requires successful negotiation of 
the ethical and R&D layers of the NHS. Differences in structure and governance frameworks feature between the 
constituent nations of the UK (England, Scotland, Wales and Northern Ireland), which adds complexity to cross-national 
studies. Difficulties in carrying out research in the NHS in the UK due to bureaucratic and time-consuming governance 
processes have led to the development of a new system of application and co-ordination from 2009. This paper 
illustrates how this new system fails to be consistent and streamlined and is unlikely to become so unless changes are 
made to the implementation and management of the governance processes.
Methods: We present a case study of the research governance process at the survey stage of an investigation into the 
use, preferences and need for information by people making choices or decisions about health care. The method 
involved home-based, face-to-face interviewing in a questionnaire survey in relation to decisions about lymphoma 
treatment, Down's syndrome screening in pregnancy, and caring for people with dementia.
Results: Our experience of the ethics stage was very positive, noting an efficient process of application and a speedy 
decision, both in relation to the initial application and to subsequent substantial amendments. By contrast, the R&D 
stages were very slow, most with unexplained delays, but some offering contradictory advice and exhibiting a lack of 
clear guidance and training for NHS staff. The R&D arrangements in Scotland were far quicker and more likely to be 
successful than in England. Overall, the delays were so severe that substantial parts of the research could not be 
delivered as planned within the funding timescale.
Conclusions: If high-quality research in the NHS, particularly in England, is to be delivered in a timely and cost-effective 
way, R&D processes for gaining research governance approval need improvement. Attention is needed in process 
implementation and management, particularly in relation to staff training, as well as clarity in guidance and 
communication within and between organisations.
Background
A new system providing a consistent and streamlined 
process for gaining NHS permission for clinical research in 
England
Against a backdrop of severe and sustained criticism of
the NHS research governance arrangements in the UK
over the last 10 years, the above strapline [1] heralded a
more efficient and integrated system for conducting
research in the NHS from 2009 onwards. This paper illus-
trates how this new system fails to be consistent and
streamlined, and is unlikely to become so unless a num-
ber of concomitant changes are made to the implementa-
tion and management of the governance processes.
Ethical approval
Ethical practice in research can be reasonably expected
by the public to be part and parcel of the normative pro-
fessional code of conduct. Nonetheless, increasing exter-
nal regulation, emanating from the Helsinki Declaration
in 1964 [2] onwards as a result of notorious aberrations in
trust, has moved ethical practice from agency-based to
institutional-based governance. Health services research
* Correspondence: Emma.France@stir.ac.uk
2 Department of Nursing & Midwifery, University of Stirling, R.G. Bomont 
Building, Stirling FK9 4LA, UK
Full list of author information is available at the end of the articleBioMed Central
© 2010 Thompson and France; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Thompson and France BMC Health Services Research 2010, 10:124
http://www.biomedcentral.com/1472-6963/10/124
Page 2 of 8in the UK has epitomised this trend. Parallel develop-
ments in the NHS and research-based organisations, such
as universities and professional organisations (e.g. Social
Research Association; British Sociological Association;
Market Research Society), have led to numerous ethical
guidelines and frameworks to which professional
researchers are expected to adhere. It is now common-
place for universities to require research proposals of any
kind, including student projects, to be submitted to an
internal ethics committee prior to fieldwork.
Researchers' frustrations, concerns and complaints
about excessive time delays in carrying out investigations
within the NHS, both clinical [3-5] and social [6-8], are
well-documented. Despite the advantages that the insti-
tutions of governance and regulation bestow upon inves-
tigators by giving licence to their activities, this does not
mean that such criticisms are over-stated, as mere "whin-
ing of a privileged community" [9]. Researchers have mul-
tiple roles to play, not simply as people skilled in the
investigatory process, but as advocates for their research
participants in giving voice to often unheard social
groups, as drivers of quality improvement through timely
publication of new knowledge, and, in the case of non-
commercial funding, as guardians of the public purse
through efficient organisation and management.
Similar developments are taking place elsewhere in the
world, at a varying pace, but in the same direction, with
related concerns about the efficacy of the governance
arrangements. There are major differences between
European countries as to what needs to be submitted to
Research Ethics Committees (RECs), with the UK being
noted as having an arduous process [10]. In the USA fed-
eral policies on human subjects research has become
strongly protectionist [11], with increased strictures on
governing research by the Institutional Review Boards
[12]. Problems in the under-resourcing and overworking,
not to mention the lack of clear accountability structures,
of Human Research Ethics Committees in Australia [13]
and Research Ethics Boards in Canada [14], have led to
demands to reform their governance systems.
The process of gaining access via the NHS to carry out
research with any person or group, be they staff, patients,
patient representatives, or even members of the public
sampled via NHS records (such as unpaid carers),
involves several stages of approval and permission. Before
anything else is the requirement to obtain ethical
approval, which, despite its bureaucratic and time-con-
suming nature [8], has shown welcome signs of improve-
ment as a result of cumulative operational changes.
Multi-centre investigations, which previously required
permission from each Local Research Ethics Committee
(LREC), each with its own idiosyncratic systems and
viewpoints [15], as well as a global view by the Multi-
Centre Research Ethics Committee (MREC), evolved by
2000 into a more co-ordinated system under the Central
Office for Research Ethics Committees (COREC), with
performance deadlines added subsequently. McDonach
et al's study in Scotland [16] reported a delay of only ten
weeks between application and approval by the MREC,
albeit requiring a further seven weeks for LRECs to con-
firm their notification of the study, while van Teijlingen et
al's study [8] received approval from the MREC within six
weeks, but was delayed by another three and a half
months awaiting endorsement by the LRECs.
In 2007 COREC was incorporated into the National
Research Ethics Service (NRES) of the National Patient
Safety Agency, which in turn developed the Integrated
Research Application System (IRAS) in 2008 (and fully
operationalised in 2009) in response to the need for "a
single online system for applying for permissions and
approvals for health and social care/community research
in the UK" [17]. For researchers working across adminis-
trative and, importantly, national boundaries within the
UK, given the devolved responsibility for the NHS, this is
potentially of great benefit.
R&D management approval
Having successfully been approved by the ethics review-
ing bodies, whose role is to ensure that the potential ben-
efits of research do not exploit or cause harm to
vulnerable participants [18], the next stage requires
obtaining Research Management and Governance
(RM&G) approval, or R&D approval as it is commonly
known, from each of the NHS service providers, to
ensure they have adequate arrangements and resources in
place to ensure quality of care, patient safety and finance
to cover staff time [19]. At this point the differences
between the nations emerge due to different NHS struc-
tures and related policies on governance. In England this
involves up to 8 types of Trust, covering more than 400
organisations [20], depending on whether the research
participants are to be sampled in primary, secondary, or
community services. By contrast, in Scotland it requires
application to any of 14 Health Boards, which work
across all services in their geographical area. Previously
multi-centre studies required application to each Trust or
Board individually, whereas under the new system one
coordinating centre is vested with the responsibility for
leading on all approvals wherever they are required in the
UK.
In 2006 the Department of Health developed a new
research framework for the NHS in England [21], to cre-
ate more cohesion between the different organisations
and funding streams and to strengthen a competitive
research framework in order to increase research invest-
ment in clinical trials by the pharmaceutical industry.
The fragmentation of the English NHS incurs greater
challenges in achieving permission in multi-centre stud-
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(NIHR), the new research arm of the NHS, has instituted
the Coordinated System for gaining NHS Permission
(NIHR CSP) to offer a 'one-stop shop' for approvals,
thereby aiming to reduce the bureaucratic burden and the
time delays that have characterised the process [22]. This
system is currently only accessed by studies in the NIHR
Clinical Research Network Portfolio via IRAS.
The responsibility for developing the NIHR CSP is
vested in the NIHR Clinical Research Network Coordi-
nating Centre (NIHR CRN CC), which undertakes global
checks; these are study-wide governance checks which
apply to all participating Trusts and that are only carried
out once for each study, such as ensuring ethical approval
is in place. The Coordinating Centre then asks the rele-
vant Comprehensive Local Research Networks (CLRN),
of which there are 25, to undertake local governance
checks on behalf of each participating service provider in
their area, before forwarding a Governance Report to
them [23]. After these approvals have been gained, it is
then the responsibility of the local Trusts to give permis-
sion through their R&D offices, either by making site-
specific assessments (SSAs) of the suitability of the NHS
research site and of local researchers in the case where
NHS staff are involved in performing the research, or by
approving the provider as a Participant Identification
Centre (PIC) when their staff are only involved in helping
a remote research team with the sampling of participants.
Given the multiplicity of layers for gaining permission to
carry out research, the effectiveness of the new coordi-
nated system in England is crucial to its success. The
comparatively simpler structure in Scotland was found by
McDonach et al [16] to require up to 33 additional weeks
to gain approvals from the 26 R&D departments involved
in their national study. The new structures for the
research governance processes in England and Scotland
are shown in Figure 1.
The implementation and failures of the latest system
that was designed to reduce bureaucracy and time delays
in research [24] can be well illustrated by a case study
based on our investigation. Our study was one of the first
to access the new IRAS application system and so pro-
vides an opportunity to test its viability and proclaimed
advantages.
Methods
Through a competitive tendering process, we secured a
contract with the NIHR Service Delivery and Organisa-
tion to investigate the use, preferences and need for infor-
mation by patients and unpaid carers to make choices
about health care [25]. The research design involved
three distinct stages that iteratively employed a variety of
methods to build a detailed and nuanced understanding
of what and how people talked about information in rela-
tion to five specific conditions. Since the first stage
involved secondary data analysis that had pre-existing
ethical approval, we decided to seek ethical permission
for the next two stages in two corresponding phases, the
first of which preceded the most recent application pro-
cess via IRAS.
The case study we describe below concerns the final
stage of this design, which involves a questionnaire sur-
vey in Scotland and England, using face-to-face, home-
based interviews, of people who faced decisions in one of
three situations: whether to have treatment for a diagno-
sis of lymphoma; whether to have an antenatal test for
Down's syndrome; and, where a person with dementia
should live by people caring for them in an unpaid capac-
ity (e.g. at their home, or in a residential or nursing care
home). Only those in the first of these groups would be
likely to be patients at the time of the study, but we
wished to sample all groups via NHS records in order to
allow a high chance of locating such people. The inten-
tion was to make generalisable estimates about the distri-
bution of experiences and opinions between and across
all groups and both nations. This necessitated random
samples being drawn on a clustered geographical basis
from secondary care lymphoma clinics and from general
practices for the two other groups. Invitations were to be
issued by the hospitals and general practices to prospec-
tive participants on our behalf. Although reflecting on
past decisions could raise respondent anxiety, the risks to
participants in such a study are believed to be very small.
The fieldwork was to be sub-contracted to a commer-
cial survey organisation due to the size of the sample nec-
essary to produce generalisable results with a high degree
of precision, estimated at 900 in total, coupled with the
need to be able to interview people in their homes over a
relatively short period in multiple locations across Scot-
land and England. Any delays would have implications for
the costs of the study, since protracted fieldwork and
uncertainties about gaining permission would add signifi-
cantly to the unanticipated costs of securing interviewers
in the field, as well as the administration costs of extend-
ing contract deadlines.
Results
Ethical approval
Due to the multi-centre nature of this research stage, eth-
ical approval was sought via one of the Research Ethics
Committees (RECs) in Scotland, which acted on behalf of
all RECs. Despite a decision being expected within the
obligatory maximum of 60 days, initial approval was
secured, with no amendments required, in only 18 work-
ing days. Three subsequent 'substantial amendments'
were submitted for approval, two relating to revisions to
the questionnaire and one a revision of the recruitment
process. These three amendments again received favour-
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within the obligatory 35 day limit. Under the new system,
once the main REC has given approval, there is no longer
a need to wait for the RECs in the other sites to approve
or acknowledge the ethical nature of the study, since this
is communicated via IRAS. Our experience of the ethical
review stage was very positive.
R&D management approval in Scotland
Research management and governance approval, the next
step in the process, proved to be a considerable impedi-
ment to the successful execution of the project. A local
NHS advisor's confusion about the nature of NHS service
providers' involvement in our study as PICs delayed by
two weeks our application to the centre that would co-
ordinate within Scotland and make links with England, in
this case the NHS Research Scotland Coordinating Cen-
tre (NRS CC). Approvals were sought from seven Health
Boards in Scotland, which were duly given over a period
of 13 to 44 (median 15) working days after receipt of ethi-
cal approval. Thus, the time taken between application
for ethical approval and confirming all RM&G permis-
sions in Scotland was 75 (median 46) working days.
R&D governance checks in England
In England the NIHR CRN CC was sent details of our
study by the NRS CC 26 working days after receipt of eth-
ical approval, although only appeared to receive the infor-
mation after a further 11 working days. Due to this being
the Scottish centre's first cross-border study under the
new system, there was some confusion about knowing
where to send the information. Unfortunately, the English
coordinating centre itself did not have a process in place
nor for guiding the CLRNs on PIC studies until 60 work-
ing days after our ethical approval was gained, before
which the global and local checks could not be started.
In order to be able to undertake the fieldwork within
the project time frame, our original deadline for receiving
approvals was in June 2009, which would have allowed 70
- 80 working days after gaining ethical approval, calcu-
Figure 1 The new NHS research governance processes in England and Scotland.
Researcher  prepares & submits ethics 
forms via IRAS for REC approval 
Researcher forwards copies of all ethics 
documents to REC
REC gives ‘favourable ethical opinion’ 
(approval)
Researcher forwards ethics approval letter 
to NHS co-ordinating centre (NRS CC)
Researcher forwards R&D documents to relevant NHS 
co-ordinating centre, in this case NRS CC in Scotland. 
NRS CC completes global checks & forwards 
documents to local R&D offices in relevant Health 
Boards in Scotland 
R&D offices perform local checks & 
grant R&D permission
Co-ordinating centre (NRS CC) forwards documents to 
other relevant co-ordinating centres (NIHR CRN CC in 
England)
tim
e
NIHR CRN CC performs global checks & 
forwards documents to relevant CLRNs 
CLRNs & Trust R&D offices perform local checks 
CLRN produces Governance Report & sends it 
to local Trust R&D office
Local Trusts grant R&D permission
CLRNs contact local Trusts 
Researcher prepares & submits R&D forms via 
IRAS for R&D approval 
Research activity can commence in specific 
Health Boards in Scotland
Research activity can commence in specific 
Trusts in England
Key
UK-wide process 
Scottish R&D process
English R&D process
Stages where problems/
delays encountered
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being reasonable when the original funding application
for the study was submitted, peer-reviewed and granted.
Due to the difficulties gaining R&D approvals, we
extended this deadline to early September 2009, requiring
a negotiated, no-cost, project extension from our funder.
Whilst the design of the study attempted to minimise
fieldwork costs by sampling in matching areas for respon-
dents recruited from primary and secondary care, it was
not always possible to identify a willing or able lymphoma
clinic, thus requiring different CLRNs to be involved. In
order to secure samples for antenatal screening and car-
ing for dementia, in England the NIHR CRN CC needed
to forward information and guidance to seven CLRNs to
carry out local governance checks on behalf of 14 Pri-
mary Care Trusts (PCTs). Similarly, for recruiting lym-
phoma patients via secondary care in England, the NIHR
CRN CC needed to contact nine CLRNs in relation to
four Acute Trusts and six Foundation Trusts. While
Trusts are able to begin their process of deciding whether
to give permission for a study, they cannot confirm this
decision until they have received the Governance Report
from their CLRN assuring them that the local governance
checks have been completed. We only received confirma-
tion (beyond our deadline) from one CLRN that checks
were complete 169 working days after ethical approval
was granted, with a warning that we could not proceed
until permission was communicated from the hospital,
which could take another 15 working days; i.e. 184 days in
all. Given that Trusts are mandated to respond within 21
days of receiving the Governance Report, we have to
assume that CLRN approvals started when the NIHR
CRN CC accepted our study into the CSP record and
were all finished 110 days later.
Trust management permission in England
Notwithstanding this delay in RM&G, we had contacted
all the local R&D offices to brief them on the study in the
hope that this would speed up the process once global
checks had been carried out. In the case of three Acute
Trusts and two Foundation Trusts, permission was
granted between 86 and 126 (median103) working days
after ethical approval, although we only managed to
secure consultants' willingness to participate in patient
recruitment in three of these Trusts (one later dropped
out of the study). A further two Acute Trusts gave per-
mission well beyond our deadline. No permission was
ever received from the remaining one Acute Trust and
two Foundation Trusts, although it is not clear if this was
due to their CLRNs failing to confirm local approval.
With respect to primary care, permission was received
from only two of the 14 PCTs by 105 working days after
ethical approval, leading us to have to abandon this part
of the study, given the additional delays likely at the next
stage when recruiting general practices. In total, the time
between application for ethical approval and those Trust
permissions that were received in England was 202 work-
ing days. The time delays in gaining approvals and per-
mission through this governance process, excluding the
CLRNs and NHS Trusts which did not respond at all, is
summarised in Figure 2.
Impact on professional recruitment
The third concurrent phase of the process of attempting
to secure approval to sample from medical records
involved the recruitment of professional staff. We were
fortunate to benefit from the help and support of the clin-
ical primary care and cancer research networks in Scot-
land and England for recruiting general practices and
lymphoma clinics, respectively.
In England, in order to secure governance approvals,
NIHR CRN CC advised us that we needed to provide
them with details of all participating PICs before gover-
nance checks could be completed and approvals given,
yet most of the Primary Care Research Networks refused
to recruit general practices until governance approvals
had been granted, citing as the reason that many studies
do not go ahead. This caused difficulties for gaining
approvals from PCTs due to the intractability of this situ-
ation. Of the two PCTs which eventually gave permission,
only a handful of GPs had agreed to act as PICs by our
extended deadline, leading to us having to abandon this
part of the study. The cancer research network did not
impose a similar requirement and we were able to recruit
consultants prior to governance approvals being granted,
although this was not without its difficulties.
General issues
By the time we drew a halt on trying to obtain R&D
approvals and permission and could begin to plan an
accurate schedule for recruiting and interviewing individ-
ual respondents, the original schedule for the fieldwork
had effectively been delayed by about 4 months, requiring
Figure 2 Time taken for NHS Governance Approvals and Permis-
sion (excluding non-responses).
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and costs of fieldwork with the subcontractor. Not only
that, but it became necessary to phase the fieldwork into
three distinct periods to reflect when samples became
available (Scottish lymphoma patients, followed by Scot-
tish primary care respondents, and finally English lym-
phoma patients), adding further costs to the study. It is
worth noting that we also had to negotiate with our
funders for an extension in the study deadline of three
months to achieve our revised and scaled-down objec-
tives, without incurring any increased costs, through a
reduction in expected sample sizes offsetting continuing
staff costs.
In managing the project we attempted to identify the
main causes of these cumulative delays, since we wished
to be able to find alternative means to resolve bottlenecks
and to provide information that might be required, even
though everything should have been available via IRAS.
Reasons for delays were rarely offered spontaneously by
CLRNs or Trusts, but only as the result of enquiries made
by the research team. The reasons included lack of famil-
iarity with the new system, in particular concerning PIC
studies, and apparent confusion over what was required
of CLRNs and Trusts; having lost or not having received
information; and waiting for information that was not
required.
CLRNs and Trust R&D departments reported finding
the hastily put together PIC guidance from NIHR CRN
CC 'cumbersome' and reported that ours was the first
study of its kind that they had been required to process
using the new system. In some instances, R&D depart-
ments informed us that they had carried out all of their
local checks but could not issue an approval until the
CLRN had completed their four checks, which for some
reason had not been completed. Other CLRNs and Trusts
mistakenly thought that our study involved NHS service
providers carrying out research activities, rather than act-
ing as PICs, and so repeatedly asked for copies of non-
existent documentation in relation to this.
More than once we were requested to provide informa-
tion that should have filtered down directly from IRAS or
the clinical research networks, which points to lack of
familiarity with the IT system. In a few cases we were
asked for 'enhanced' Disclosure (Scotland) or Criminal
Records Bureau (England) checks, or occupational health
checks, that most providers, rightly or wrongly, did not
consider necessary.
In summary, from applying for ethics approval, through
the minefield of RM&G approvals and recruitment of
professionals, to securing respondents to our samples has
taken almost a year, involving substantial additional work
in progress chasing. The processes in place have led to a
patchy response, which in England has resulted in just
two lymphoma centres and a complete absence of pri-
mary care to sample the other two conditions, thus pre-
venting generalisation at the national level. These
problems have prevented us gaining timely RM&G
approvals and permissions, which threaten the scientific
integrity of the study, making it difficult to reach mean-
ingful and robust conclusions.
Discussion
The need for governance in health-related research, both
for affirming its ethical status and for ensuring that the
services have the capacity to support it, is not under dis-
pute by the vast majority of the research community.
However, there are major concerns about whether cur-
rent governance arrangements are appropriate to the task
and able to provide timely and genuinely supportive sys-
tems to investigators. That systems require a number of
iterations before they achieve their aims is not a new or
surprising phenomenon, but the current arrangements in
the NHS within the UK do not yet reflect what is claimed
for them.
It would appear from our case study and those quoted
earlier [8,16] that there is no necessary delay in gaining
ethical approval under the current framework, at least
not for relatively low-risk projects using PICs, such as
ours. The main time-consuming activity is in writing the
extensive on-line application form, but the new IRAS sys-
tem has been designed to minimise the amount of dupli-
cation of requests for information and to provide an
automatic forwarding of relevant sections to downstream
governance bodies.
Without a doubt the major part of the governance
problem that we encountered was in the RM&G process.
The newly launched NIHR CSP, while supported by a
clear and reasonably efficient IRAS application process,
did not initially have the necessary processes in place for
dealing with all types of study, such as those involving
PICs in our case. Once the protocol for PICs had been
agreed the governance checks could move ahead, but it
does not explain why the CLRNs still required so much
time for the local checks, nor why some never responded.
While CLRNs were not subject to a time target, due
apparently to the number of variables involved [26], the
permission from local NHS providers was required
within 21 days of receiving the Governance Report. It
begs the question of why so many providers never replied
at all. The espoused benefit of the NIHR CSP providing a
"high quality process" [1] would seem rather premature.
By contrast, the governance process in Scotland was, in
our experience, a much easier and quicker system
through which to gain the necessary approvals and per-
mission. A major factor is likely to be the less fragmented
nature of NHS Scotland, with its single authority struc-
ture of Health Boards, probably supported by a closer
network of research support. All except one Health Board
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ahead, which was granted soon after receiving ethical
approval. The rare examples of confusion about the regu-
lations concerning PICs were relatively quickly resolved
once we discussed the IRAS guidance with them. The
communication difficulty between the Scottish and Eng-
lish co-ordinating centres slowed down the process, but
may be symptomatic of the teething problems of learning
a new system for cross-border studies.
Where difficulties or delays occurred, we only discov-
ered them through repeated requests for status reports,
rather than there being a sense of partnership in the pro-
cess. Neither we nor our funders had any managerial con-
trol over this process, which, we would argue, requires
responsibility being taken up by local management within
some nationally agreed guidance.
Implementation of policy such as this is dependent
upon an adequate level of resources being made available
in a timely fashion, as well as a comprehensive training
package for staff at the different levels, supported by
transparent and accessible guidance.
The narrative we have presented in this case study
offers a detailed description of the difficult journey that
faces investigators attempting to sample within the NHS
in England, in particular, and to a much lesser extent in
Scotland. A limitation of this study is that, being a single
case, it may not be generalisable to the experiences of
other researchers. However, many of the problems we
faced at the level of service provider were not new and,
even if some of them were teething problems in the new
arrangements, there are still worrying examples of lack of
forethought, resources and management in the imple-
mentation stage, which will require deliberate action to
resolve.
Conclusions
Ethical approval for health-care research is carried out by
independent committees, which, in attempting to protect
research participants, consider not only the risks, consent
procedures and data confidentiality, but also the scientific
importance and research design of the study [27]. Whilst
it does raise questions about why ethics committees
might be duplicating the work of funding organisations in
carrying out what is in large part a peer review of the
research itself, part of a phenomenon known as 'ethics
creep' [28], there are arguments to value this process of
reflection on the process. To a large extent the lengthy
application form should be relatively straightforward,
given the tendering process which probably preceded it.
The recent history of gaining governance approvals and
permission to approach staff or people registered on
medical records has necessitated a much less bureau-
cratic and streamlined system for research to be estab-
lished in the NHS in the UK. The new system introduced
with full effect from 2009 should have some benefits over
the previous system, insofar as it provides a single point
of application (IRAS) through a more coherent software
package, which has led to less duplication of the informa-
tion that is requested. In addition there are reasonable
time targets for gaining ethical approval and for NHS
providers to give permission, once the up-stream clinical
research network approvals have been given.
Unfortunately, the disadvantages of the current system
continue to thwart the delivery of well-conducted and
timely research. Unnecessary duplication still exists
between the different levels of the governance frame-
work, partly because of lack of understanding or clarity of
the new regulations in place. There is a lack of over-arch-
ing time targets for the entire RM&G process, in particu-
lar relating to CLRNs in England, an apparent lack of any
requirement to respond at all, either to give or withhold
permission, and, as a result, the higher likelihood of stud-
ies being abandoned, or reduced in scope and depth. The
consequence is a threat to the scientific contribution that
research can deliver for the funds allocated.
We would support the recommendation of Appleton
and colleagues [29] that a collaborative framework be set
up that brings together researchers and those vested with
responsibility for designing and implementing research
governance processes, extending it to cover the whole of
the NHS. A clear communications strategy needs to be in
place to ensure all parts of the system are in harmony and
understand what is required, supported by properly-
financed training and IT systems. Despite the difficulties
of dealing with the many variables at play, there needs to
be a limit on the time taken by any part of the system,
especially CLRNs, to approve or disapprove a research
project taking place, and, in the case of the latter decision,
with clear explanations as to why it has failed. An inter-
esting question for the NIHR to answer would be the
opportunity cost of research projects that have been
abandoned or reduced in scope as a result of failures in
the RM&G approvals process for reasons other than poor
science.
The end results of the problems and deficiencies in the
current process are inevitably poorer research outputs,
with quantitative studies being underpowered and proba-
bly unrepresentative, difficulties in fulfilling the social
justice agenda of giving voice to unheard population
groups, lower efficiency and ultimately poorer value for
money.
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